Updates to Disaster Management Strategies for CDC Category A Bioterrorism Agents
AbstractPurpose of ReviewThe goal of this paper is to provide current suggestions for a system-based response to a bioterrorism attack and discuss treatment options for CDC category A bioterrorism agents.Recent FindingsVaccines for anthrax andY. pestis are being developed, but they are not rapidly available in the USA. Vaccine distribution methodology for the recent M-pox outbreak was used that the smallpox vaccine could utilize. Two antibody therapies and one vaccine are available for Ebola but not for other viral hemorrhagic fever diseases. Recent health system stressors encountered during the COVID-19 pandemic are likel...
Source: Current Emergency and Hospital Medicine Reports - April 22, 2024 Category: Emergency Medicine Source Type: research
Helminth exposure and immune response to the two-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccine regimen
In this study, we aimed to assess the association between helminth exposure to the most prevalent parasitic infections, schistosomiasis, soil transmitted helminths infection and filariasis, and the Ebola virus glycoprotein (EBOV GP) antibody concentration in response to vaccination with the Ad26.ZEBOV, MVA-BN-Filo vaccine regimen in African and European participants using samples obtained from three international clinical trials. Methods/Principal findingsWe conducted a study in a subset of participants in the EBL2001, EBL2002 and EBL3001 clinical trials that evaluated the Ad26.ZEBOV, MVA-BN-Filo vaccine regimen against EV...
Source: PLoS Neglected Tropical Diseases - April 11, 2024 Category: Tropical Medicine Authors: Houreratou Barry Source Type: research
Perceptions, attitudes, and willingness of healthcare and frontline workers to participate in an Ebola vaccine trial in Uganda
CONCLUSIONS: Overall, information sharing leads to a better understanding and acceptance of vaccine trials and a positive vaccination experience can be a deciding factor in the acceptance of others. Particular attention should be paid to involving the community in addressing misconceptions and fears, while ensuring that participants have access to vaccination sites in terms of transport, and that they are properly accommodated at the study site including staying for a reasonable period of time.PMID:38565464 | DOI:10.1016/j.vaccine.2024.03.053 (Source: Vaccine)
Source: Vaccine - April 2, 2024 Category: Allergy & Immunology Authors: Geofrey Kimbugwe Renaud Vatrinet Juliet A Mwanga Ronald Kakuru Doreen Mpeirwe Suzan Logoose Kimton Opio Mateus Kambale Janet Seeley Rebecca F Grais Caroline Marquer Pontiano Kaleebu Agnes Ssali Source Type: research
Perceptions, attitudes, and willingness of healthcare and frontline workers to participate in an Ebola vaccine trial in Uganda
CONCLUSIONS: Overall, information sharing leads to a better understanding and acceptance of vaccine trials and a positive vaccination experience can be a deciding factor in the acceptance of others. Particular attention should be paid to involving the community in addressing misconceptions and fears, while ensuring that participants have access to vaccination sites in terms of transport, and that they are properly accommodated at the study site including staying for a reasonable period of time.PMID:38565464 | DOI:10.1016/j.vaccine.2024.03.053 (Source: Vaccine)
Source: Vaccine - April 2, 2024 Category: Allergy & Immunology Authors: Geofrey Kimbugwe Renaud Vatrinet Juliet A Mwanga Ronald Kakuru Doreen Mpeirwe Suzan Logoose Kimton Opio Mateus Kambale Janet Seeley Rebecca F Grais Caroline Marquer Pontiano Kaleebu Agnes Ssali Source Type: research
Effects of Shock and Vibration on Product Quality during Last-Mile Transportation of Ebola Vaccine under Refrigerated Conditions < sup > 1 < /sup >
Emerg Infect Dis. 2024 Apr;30(4):757-760. doi: 10.3201/eid3004.231060.ABSTRACTAnalyzing vaccine stability under different storage and transportation conditions is critical to ensure that effectiveness and safety are not affected by distribution. In a simulation of the last mile in the supply chain, we found that shock and vibration had no effect on Ad26.ZEBOV/MVA-BN-Filo Ebola vaccine regimen quality under refrigerated conditions.PMID:38526137 | DOI:10.3201/eid3004.231060 (Source: Emerging Infectious Diseases)
Source: Emerging Infectious Diseases - March 25, 2024 Category: Infectious Diseases Authors: Linda Bus-Jacobs Rute Lau Marjolein Soethoudt Lisa Gebbia Edwin Janssens Tjeerd Hermans Source Type: research
Effects of Shock and Vibration on Product Quality during Last-Mile Transportation of Ebola Vaccine under Refrigerated Conditions < sup > 1 < /sup >
Emerg Infect Dis. 2024 Apr;30(4):757-760. doi: 10.3201/eid3004.231060.ABSTRACTAnalyzing vaccine stability under different storage and transportation conditions is critical to ensure that effectiveness and safety are not affected by distribution. In a simulation of the last mile in the supply chain, we found that shock and vibration had no effect on Ad26.ZEBOV/MVA-BN-Filo Ebola vaccine regimen quality under refrigerated conditions.PMID:38526137 | DOI:10.3201/eid3004.231060 (Source: Emerging Infectious Diseases)
Source: Emerging Infectious Diseases - March 25, 2024 Category: Infectious Diseases Authors: Linda Bus-Jacobs Rute Lau Marjolein Soethoudt Lisa Gebbia Edwin Janssens Tjeerd Hermans Source Type: research
Effects of Shock and Vibration on Product Quality during Last-Mile Transportation of Ebola Vaccine under Refrigerated Conditions < sup > 1 < /sup >
Emerg Infect Dis. 2024 Apr;30(4):757-760. doi: 10.3201/eid3004.231060.ABSTRACTAnalyzing vaccine stability under different storage and transportation conditions is critical to ensure that effectiveness and safety are not affected by distribution. In a simulation of the last mile in the supply chain, we found that shock and vibration had no effect on Ad26.ZEBOV/MVA-BN-Filo Ebola vaccine regimen quality under refrigerated conditions.PMID:38526137 | DOI:10.3201/eid3004.231060 (Source: Emerging Infectious Diseases)
Source: Emerging Infectious Diseases - March 25, 2024 Category: Infectious Diseases Authors: Linda Bus-Jacobs Rute Lau Marjolein Soethoudt Lisa Gebbia Edwin Janssens Tjeerd Hermans Source Type: research
Effects of Shock and Vibration on Product Quality during Last-Mile Transportation of Ebola Vaccine under Refrigerated Conditions < sup > 1 < /sup >
Emerg Infect Dis. 2024 Apr;30(4):757-760. doi: 10.3201/eid3004.231060.ABSTRACTAnalyzing vaccine stability under different storage and transportation conditions is critical to ensure that effectiveness and safety are not affected by distribution. In a simulation of the last mile in the supply chain, we found that shock and vibration had no effect on Ad26.ZEBOV/MVA-BN-Filo Ebola vaccine regimen quality under refrigerated conditions.PMID:38526137 | PMC:PMC10977826 | DOI:10.3201/eid3004.231060 (Source: Emerging Infectious Diseases)
Source: Emerging Infectious Diseases - March 25, 2024 Category: Infectious Diseases Authors: Linda Bus-Jacobs Rute Lau Marjolein Soethoudt Lisa Gebbia Edwin Janssens Tjeerd Hermans Source Type: research
Effects of Shock and Vibration on Product Quality during Last-Mile Transportation of Ebola Vaccine under Refrigerated Conditions < sup > 1 < /sup >
Emerg Infect Dis. 2024 Apr;30(4):757-760. doi: 10.3201/eid3004.231060.ABSTRACTAnalyzing vaccine stability under different storage and transportation conditions is critical to ensure that effectiveness and safety are not affected by distribution. In a simulation of the last mile in the supply chain, we found that shock and vibration had no effect on Ad26.ZEBOV/MVA-BN-Filo Ebola vaccine regimen quality under refrigerated conditions.PMID:38526137 | PMC:PMC10977826 | DOI:10.3201/eid3004.231060 (Source: Emerging Infectious Diseases)
Source: Emerging Infectious Diseases - March 25, 2024 Category: Infectious Diseases Authors: Linda Bus-Jacobs Rute Lau Marjolein Soethoudt Lisa Gebbia Edwin Janssens Tjeerd Hermans Source Type: research
Effects of Shock and Vibration on Product Quality during Last-Mile Transportation of Ebola Vaccine under Refrigerated Conditions < sup > 1 < /sup >
Emerg Infect Dis. 2024 Apr;30(4):757-760. doi: 10.3201/eid3004.231060.ABSTRACTAnalyzing vaccine stability under different storage and transportation conditions is critical to ensure that effectiveness and safety are not affected by distribution. In a simulation of the last mile in the supply chain, we found that shock and vibration had no effect on Ad26.ZEBOV/MVA-BN-Filo Ebola vaccine regimen quality under refrigerated conditions.PMID:38526137 | PMC:PMC10977826 | DOI:10.3201/eid3004.231060 (Source: Emerging Infectious Diseases)
Source: Emerging Infectious Diseases - March 25, 2024 Category: Infectious Diseases Authors: Linda Bus-Jacobs Rute Lau Marjolein Soethoudt Lisa Gebbia Edwin Janssens Tjeerd Hermans Source Type: research
Lot-to-lot consistency, immunogenicity, and safety of the Ad26.ZEBOV, MVA-BN-Filo Ebola virus vaccine regimen: A phase 3, randomized, double-blind, placebo-controlled trial
Volume 20, Issue 1, December 2024 . (Source: Human Vaccines and Immunotherapeutics)
Source: Human Vaccines and Immunotherapeutics - March 25, 2024 Category: Allergy & Immunology Authors: Neil GoldsteinChelsea McLeanAuguste GaddahJoachim DouaBabajide KeshinroLinda Bus-JacobsJenny HendriksKerstin LuhnCynthia RobinsonMacaya Douoguiha Janssen Vaccines & Prevention B.V, Leiden, The Netherlandsb Janssen Research & Development, Beerse, Belgium Source Type: research
Vaccine Development
This article considers ethical considerations surrounding pediatric vaccine development for pandemic preparedness, examines some historical cases of pediatric vaccines developed during past smallpox, influenza, and 2019 coronavirus disease pandemics, and discusses the current state of vaccine development for pandemic preparedness, including vaccines against smallpox/mpox, influenza, anthrax, and Ebola that are included in the US Strategic National Stockpile and vaccines being developed against priority pathogens identified by the World Health Organization. (Source: Pediatric Clinics of North America)
Source: Pediatric Clinics of North America - March 12, 2024 Category: Pediatrics Authors: Elizabeth A.D. Hammershaimb, James D. Campbell Source Type: research
Broad antibody and T cell responses to Ebola, Sudan, and Bundibugyo ebolaviruses using mono- and multi-valent adjuvanted glycoprotein vaccines
Antiviral Res. 2024 Mar 6:105851. doi: 10.1016/j.antiviral.2024.105851. Online ahead of print.ABSTRACTCurrently, there are two approved vaccine regimens designed to prevent Ebola virus (EBOV) disease (EVD). Both are virus-vectored, and concerns about cold-chain storage and pre-existing immunity to the vectors warrant investigating additional vaccine strategies. Here, we have explored the utility of adjuvanted recombinant glycoproteins (GPs) from ebolaviruses Zaire (EBOV), Sudan (SUDV), and Bundibugyo (BDBV) for inducing antibody (Ab) and T cell cross-reactivity. Glycoproteins expressed in insect cells were administered to ...
Source: Antiviral Research - March 8, 2024 Category: Virology Authors: Jiin Felgner Elizabeth Clarke Jenny E Hernandez-Davies Sharon Jan Ariel Wirchnianski Aarti Jain Rie Nakajima Algimantas Jasinskas Erwin Strahsberger Kartik Chandran Steven Bradfute D Huw Davies Source Type: research
Broad antibody and T cell responses to Ebola, Sudan, and Bundibugyo ebolaviruses using mono- and multi-valent adjuvanted glycoprotein vaccines
Antiviral Res. 2024 Mar 6:105851. doi: 10.1016/j.antiviral.2024.105851. Online ahead of print.ABSTRACTCurrently, there are two approved vaccine regimens designed to prevent Ebola virus (EBOV) disease (EVD). Both are virus-vectored, and concerns about cold-chain storage and pre-existing immunity to the vectors warrant investigating additional vaccine strategies. Here, we have explored the utility of adjuvanted recombinant glycoproteins (GPs) from ebolaviruses Zaire (EBOV), Sudan (SUDV), and Bundibugyo (BDBV) for inducing antibody (Ab) and T cell cross-reactivity. Glycoproteins expressed in insect cells were administered to ...
Source: Cell Research - March 8, 2024 Category: Cytology Authors: Jiin Felgner Elizabeth Clarke Jenny E Hernandez-Davies Sharon Jan Ariel Wirchnianski Aarti Jain Rie Nakajima Algimantas Jasinskas Erwin Strahsberger Kartik Chandran Steven Bradfute D Huw Davies Source Type: research
The Current Pathogenicity and Potential Risk Evaluation of Marburg Virus to Cause Mysterious "Disease X"-An Update on Recent Evidences
Environ Health Insights. 2024 Mar 4;18:11786302241235809. doi: 10.1177/11786302241235809. eCollection 2024.ABSTRACTThe World Health Organization (WHO) defined Disease X as an upcoming disease with the potential to cause a pandemic. Pathogen X is responsible for Disease X. Marburg virus disease (MVD) is one of the diseases from the priority disease list published by WHO. Marburg virus is a filamentous, negative-sense RNA virus that belongs to the same filovirus family as the lethal Ebola virus. Since the first discovery of this virus in 1967, 17 outbreaks occurred sporadically till 2023. Rousettus aegyptiacus acts as the na...
Source: Environmental Health Insights - March 5, 2024 Category: Environmental Health Authors: Rahima Akter Mitu Md Rabiul Islam Source Type: research
